A citation-based method for searching scientific literature

J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed, M Wadelius, T E Klein, R B Altman. Clin Pharmacol Ther 2011
Times Cited: 438







List of co-cited articles
763 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
Elena Ratner, Mohan Bala, Melinda Louie-Gao, Ebru Aydin, Sebastien Hazard, Priscilla K Brastianos. Gynecol Oncol 2019
22
4

PGxO and PGxLOD: a reconciliation of pharmacogenomic knowledge of various provenances, enabling further comparison.
Pierre Monnin, Joël Legrand, Graziella Husson, Patrice Ringot, Andon Tchechmedjiev, Clément Jonquet, Amedeo Napoli, Adrien Coulet. BMC Bioinformatics 2019
6
16

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, Stefano Grosso, Francesca Molinari, Teresa Macarulla, Mariangela Russo, Carlotta Cancelliere, Davide Zecchin, Luca Mazzucchelli,[...]. J Clin Invest 2010
293
1

Pharmacogenomics and individualized medicine: translating science into practice.
K R Crews, J K Hicks, C-H Pui, M V Relling, W E Evans. Clin Pharmacol Ther 2012
145
1

Genomic Information for Clinicians in the Electronic Health Record: Lessons Learned From the Clinical Genome Resource Project and the Electronic Medical Records and Genomics Network.
Marc S Williams, Casey Overby Taylor, Nephi A Walton, Scott R Goehringer, Samuel Aronson, Robert R Freimuth, Luke V Rasmussen, Eric S Hall, Cynthia A Prows, Wendy K Chung,[...]. Front Genet 2019
20
5

Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness.
Yiqing Zhao, Saravut J Weroha, Ellen L Goode, Hongfang Liu, Chen Wang. BMC Med Inform Decis Mak 2021
3
33

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Filip Janku, Jennifer J Wheler, Shannon N Westin, Stacy L Moulder, Aung Naing, Apostolia M Tsimberidou, Siqing Fu, Gerald S Falchook, David S Hong, Ignacio Garrido-Laguna,[...]. J Clin Oncol 2012
364
1

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer.
Malachi Griffith, Nicholas C Spies, Kilannin Krysiak, Joshua F McMichael, Adam C Coffman, Arpad M Danos, Benjamin J Ainscough, Cody A Ramirez, Damian T Rieke, Lynzey Kujan,[...]. Nat Genet 2017
296
1

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Sherene Loi, Stefan Michiels, Jose Baselga, John M S Bartlett, Sandeep K Singhal, Vicky S Sabine, Andrew H Sims, Tarek Sahmoud, J Michael Dixon, Martine J Piccart,[...]. PLoS One 2013
58
1

Genetic testing and medical decision making.
V F Reyna, F J Lloyd, P Whalen. Arch Intern Med 2001
35
2

Building individualized medicine: prevention of adverse reactions to warfarin therapy.
Evgeny Krynetskiy, Patrick McDonnell. J Pharmacol Exp Ther 2007
36
2

Towards pharmacogenomics knowledge discovery with the semantic web.
Michel Dumontier, Natalia Villanueva-Rosales. Brief Bioinform 2009
30
3


Pharmacogenomics steps toward personalized medicine.
Hong-Guang Xie, Felix W Frueh. Per Med 2005
39
2

Electronic medical records as a tool in clinical pharmacology: opportunities and challenges.
D M Roden, H Xu, J C Denny, R A Wilke. Clin Pharmacol Ther 2012
33
3

Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
Mohammad Fereidouni, Maryam Moossavi, Touba Kazemi, Shaghayeghsadat Nouranihassankiade, Arghavan Asghari. J Cell Biochem 2019
3
33

The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.
Ari Allyn-Feuer, Alex Ade, Jasmine A Luzum, Gerald A Higgins, Brian D Athey. Pharmacogenomics 2018
2
50

Azathioprine-induced warfarin resistance.
Sara R Vazquez, Matthew T Rondina, Robert C Pendleton. Ann Pharmacother 2008
24
4

Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Mahmut Özer, Yeliz Demirci, Candan Hizel, Sabit Sarikaya, İskender Karalti, Çiğdem Kaspar, Serdar Alpan, Ece Genç. Basic Clin Pharmacol Toxicol 2013
23
4


Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
Maryam H Alrashid, Ahmad Al-Serri, Salem H Alshemmari, Philip Koshi, Suzanne A Al-Bustan. Mol Diagn Ther 2016
9
11

Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.
Alice Matimba, Jurgen Del-Favero, Christine Van Broeckhoven, Collen Masimirembwa. Hum Genomics 2009
65
1

Venous thromboembolism in inflammatory bowel disease.
Kimberly Cheng, Adam S Faye. World J Gastroenterol 2020
40
2

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
Barry P King, Tayyaba I Khan, Guruprasad P Aithal, Farhad Kamali, Ann K Daly. Pharmacogenetics 2004
77
1

Intravenous warfarin as an alternative for anticoagulation.
Rochelle M Gellatly. Pharmacotherapy 2007
8
12


Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
P H O'Donnell, N Wadhwa, K Danahey, B A Borden, S M Lee, J P Hall, C Klammer, S Hussain, M Siegler, M J Sorrentino,[...]. Clin Pharmacol Ther 2017
56
1

A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders.
Francis X Brennan, Kathryn R Gardner, Jay Lombard, Roy H Perlis, Maurizio Fava, Herbert W Harris, Rachel Scott. Prim Care Companion CNS Disord 2015
30
3

Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.
Nicholas J Keeling, Meagen M Rosenthal, Donna West-Strum, Amit S Patel, Cyrine E Haidar, James M Hoffman. Genet Med 2019
38
2


An Evidence Framework for Genetic Testing.
Sharon F Terry. Genet Test Mol Biomarkers 2017
3
33

A brighter future for the implementation of pharmacogenomic testing.
Cathelijne H van der Wouden, Jesse J Swen, Matthias Samwald, Christina Mitropoulou, Matthias Schwab, Henk-Jan Guchelaar. Eur J Hum Genet 2016
18
5

Physician response to implementation of genotype-tailored antiplatelet therapy.
J F Peterson, J R Field, K M Unertl, J S Schildcrout, D C Johnson, Y Shi, I Danciu, J H Cleator, J M Pulley, J A McPherson,[...]. Clin Pharmacol Ther 2016
40
2

Optimization of initial tacrolimus dose using pharmacogenetic testing.
E Thervet, M A Loriot, S Barbier, M Buchler, M Ficheux, G Choukroun, O Toupance, G Touchard, C Alberti, P Le Pogamp,[...]. Clin Pharmacol Ther 2010
254
1


Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Ursula Amstutz, Neil H Shear, Michael J Rieder, Soomi Hwang, Vincent Fung, Hidefumi Nakamura, Mary B Connolly, Shinya Ito, Bruce C Carleton. Epilepsia 2014
127
1

Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.
Kristin W Weitzel, D Max Smith, Amanda R Elsey, Benjamin Q Duong, Benjamin Burkley, Michael Clare-Salzler, Yan Gong, Tara A Higgins, Benjamin Kong, Taimour Langaee,[...]. Clin Transl Sci 2018
18
5


Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Philip E Empey, James M Stevenson, Sony Tuteja, Kristin W Weitzel, Dominick J Angiolillo, Amber L Beitelshees, James C Coons, Julio D Duarte, Francesco Franchi, Linda J B Jeng,[...]. Clin Pharmacol Ther 2018
73
1

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
L H Cavallari, A L Beitelshees, K V Blake, L G Dressler, J D Duarte, A Elsey, J N Eichmeyer, P E Empey, J P Franciosi, J K Hicks,[...]. Clin Transl Sci 2017
58
1

The IGNITE network: a model for genomic medicine implementation and research.
Kristin Wiisanen Weitzel, Madeline Alexander, Barbara A Bernhardt, Neil Calman, David J Carey, Larisa H Cavallari, Julie R Field, Diane Hauser, Heather A Junkins, Phillip A Levin,[...]. BMC Med Genomics 2016
145
1



Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Masato Saito, Norio Yasui-Furukori, Tsukasa Uno, Takenori Takahata, Kazunobu Sugawara, Akihiro Munakata, Tomonori Tateishi. Br J Clin Pharmacol 2005
37
2

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Filip Milosavljevic, Nikola Bukvic, Zorana Pavlovic, Cedo Miljevic, Vesna Pešic, Espen Molden, Magnus Ingelman-Sundberg, Stefan Leucht, Marin M Jukic. JAMA Psychiatry 2021
34
2

Opportunities for pharmacists to integrate pharmacogenomics into clinical practice.
Yan-Ting Wang, Man Yee Merl, Jun Yang, Zhi-Xiang Zhu, Guo-Hui Li. Pharmacogenomics J 2020
16
6


A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.
David A Mrazek, John C Hornberger, C Anthony Altar, Irina Degtiar. Psychiatr Serv 2014
291
1


Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
David W Oslin, Kevin G Lynch, Mei-Chiung Shih, Erin P Ingram, Laura O Wray, Sara R Chapman, Henry R Kranzler, Joel Gelernter, Jeffrey M Pyne, Annjanette Stone,[...]. JAMA 2022
10
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.